Reflections on the Fidabio US User Group Meeting

At the recent FidaBio US User Group Meeting held in Boston, Duncan Smith was invited to give a talk highlighting how the Fida technology has had an impact on several of our recent drug discovery projects. For the last 18 months we’ve been using Fida to both support new studies and delve further into long-running projects to reveal new insights into how these proteins behave.

Duncan had been looking forward to this meeting since attending the European User Group Meeting in Copenhagen in March 2023. “It was fantastic to be invited to this meeting and given the opportunity to expand on the poster we presented at ELRIG Drug Discovery last year” says Duncan, “The Fida platform has proved to be remarkably versatile, and we’ve ended up doing more analysis of protein-small molecule interactions than we thought would be possible. It was a fantastic opportunity to meet other members of the community as well as the rapidly growing FidaBio US team. Everyone at the meeting was using the technology for a different application – and chatting over coffee we easily came up with a few more! Fida lets us do initial studies easily, with small sample consumption and a fast turnaround on the all-important first result.”

Fida’s power and versatility extends to studying proteins in solution, analysis of protein-protein interactions, affinity measurement, protein stability studies, oligomeric state and fibril formation analysis and much more. Analysis can be conducted in any buffer, including serum and lysates. At Peak Proteins we offer bespoke study designs tailored to your project requirements, including custom protein production.

For more information or to discuss your project in more detail, please get in touch with our team. info@peakproteins.com